HELPING THE OTHERS REALIZE THE ADVANTAGES OF ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC)

These side effects were being notably milder as compared to an inhibitor of both bromodomains. A detailed molecular Investigation also uncovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen TaylorGeneral, our present work highlights the potential utilization of ARV-825 in combination